216 related articles for article (PubMed ID: 11842446)
1. Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine.
Hatzidimitriou G; Tsai EH; McCann UD; Ricaurte GA
Synapse; 2002 Apr; 44(1):51-7. PubMed ID: 11842446
[TBL] [Abstract][Full Text] [Related]
2. Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration.
Winsauer PJ; McCann UD; Yuan J; Delatte MS; Stevenson MW; Ricaurte GA; Moerschbaecher JM
Psychopharmacology (Berl); 2002 Feb; 159(4):388-96. PubMed ID: 11823891
[TBL] [Abstract][Full Text] [Related]
3. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
McCann UD; Eligulashvili V; Mertl M; Murphy DL; Ricaurte GA
Psychopharmacology (Berl); 1999 Nov; 147(1):56-65. PubMed ID: 10591869
[TBL] [Abstract][Full Text] [Related]
4. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist.
Piper BJ; Vu HL; Safain MG; Oliver AJ; Meyer JS
J Pharmacol Exp Ther; 2006 May; 317(2):838-49. PubMed ID: 16434566
[TBL] [Abstract][Full Text] [Related]
5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
6. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine.
Callahan BT; Cord BJ; Ricaurte GA
Synapse; 2001 May; 40(2):113-21. PubMed ID: 11252022
[TBL] [Abstract][Full Text] [Related]
7. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
Wang X; Baumann MH; Xu H; Rothman RB
Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
[TBL] [Abstract][Full Text] [Related]
8. MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition.
Gyongyosi N; Balogh B; Kirilly E; Kitka T; Kantor S; Bagdy G
Brain Res; 2008 Sep; 1231():34-46. PubMed ID: 18638459
[TBL] [Abstract][Full Text] [Related]
9. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.
Bankson MG; Cunningham KA
J Pharmacol Exp Ther; 2001 Jun; 297(3):846-52. PubMed ID: 11356903
[TBL] [Abstract][Full Text] [Related]
10. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.
Sanchez V; O'shea E; Saadat KS; Elliott JM; Colado MI; Green AR
J Psychopharmacol; 2004 Sep; 18(3):412-6. PubMed ID: 15358986
[TBL] [Abstract][Full Text] [Related]
11. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field.
Mechan AO; Moran PM; Elliott M; Young AJ; Joseph MH; Green R
Psychopharmacology (Berl); 2002 Jan; 159(2):167-75. PubMed ID: 11862345
[TBL] [Abstract][Full Text] [Related]
12. Effect of a serotonin depleting regimen of 3,4-methylenedioxymethamphetamine (MDMA) on the subsequent stimulation of acetylcholine release in the rat prefrontal cortex.
Nair SG; Gudelsky GA
Brain Res Bull; 2006 Apr; 69(4):382-7. PubMed ID: 16624669
[TBL] [Abstract][Full Text] [Related]
13. Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release.
Jones K; Brennan KA; Colussi-Mas J; Schenk S
Addict Biol; 2010 Jul; 15(3):289-98. PubMed ID: 20477756
[TBL] [Abstract][Full Text] [Related]
14. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine.
Colado MI; O'Shea E; Granados R; Murray TK; Green AR
Br J Pharmacol; 1997 Jul; 121(5):889-900. PubMed ID: 9222545
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a role of energy dysregulation in the MDMA-induced depletion of brain 5-HT.
Darvesh AS; Gudelsky GA
Brain Res; 2005 Sep; 1056(2):168-75. PubMed ID: 16098955
[TBL] [Abstract][Full Text] [Related]
16. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery.
Hatzidimitriou G; McCann UD; Ricaurte GA
J Neurosci; 1999 Jun; 19(12):5096-107. PubMed ID: 10366642
[TBL] [Abstract][Full Text] [Related]
17. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval.
Nappi RE; Sances G; Brundu B; De Taddei S; Sommacal A; Ghiotto N; Polatti F; Nappi G
Hum Reprod; 2005 Dec; 20(12):3423-8. PubMed ID: 16123089
[TBL] [Abstract][Full Text] [Related]
18. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.
Reneman L; de Win MM; van den Brink W; Booij J; den Heeten GJ
J Psychopharmacol; 2006 Mar; 20(2):164-75. PubMed ID: 16510475
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain.
Bull EJ; Porkess V; Rigby M; Hutson PH; Fone KC
J Psychopharmacol; 2006 Mar; 20(2):272-80. PubMed ID: 16510485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
